Company: ARTL
Filing Date: 2025-09-04
Form Type: 424B5
Source: 0001640334-25-001622
Chunk: 0

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-09-04
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-273153

PROSPECTUS SUPPLEMENT

(To Prospectus dated July 14, 2023)

<div align='center'>Up to $3,451,527

Shares of Common Stock</div>

This prospectus supplement amends and supplements the information in the prospectus supplement, dated July 18, 2025 (the “ATM Prospectus”), relating to the offer and sale of up to $6,500,000 shares of our common stock, $0.001 par value per share (“Common Stock”), pursuant to the At the Market Offering Agreement between us and R.F. Lafferty & Co., Inc., as exclusive sales agent (who we refer to herein as “Lafferty” or the “Sales Agent”), dated July 18, 2025 (the “Sales Agreement”). This prospectus supplement should be read in conjunction with the ATM Prospectus and the base prospectus, dated July 7, 2023 (the “Base Prospectus”), and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus or the Base Prospectus. This prospectus supplement is not complete without and may only be delivered or utilized in connection with the ATM Prospectus and the Base Prospectus and any future amendments or supplements thereto.

The Common Stock is listed on The Nasdaq Capital Market tier of The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “ARTL.” As of September 3, 2025, the last reported sales price of the Common Stock on Nasdaq was $8.76.

We are filing this prospectus supplement to supplement and amend, as of September 4, 2025, the ATM Prospectus and the Base Prospectus, to reduce the maximum aggregate gross sales price of our Common Stock that may be offered, issued and sold under the Sales Agreement from and after the date hereof to $3,451,527 (the “ATM Offering Size Reduction”), including the Common Stock previously sold. Under the ATM Prospectus, we initially registered up to $6,500,000 of our Common Stock for offer and sale pursuant to the Sales Agreement. As of the date of the filing of this prospectus supplement, we have sold $451,526.95 shares of Common Stock that are covered by the ATM Prospectus.

The purpose of this prospectus supplement is to update